期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 213, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.113044
关键词
Matrix metalloproteinase; Gelatinase inhibitor; Cancer; Medicinal chemistry; Hydroxamate
资金
- Indian Council of Medical Research (ICMR), New Delhi, India [45/29/2019-PHA]
- Council of Scientific and Industrial Research (CSIR), New Delhi, India [09/096(0967)/2019-EMR-I]
- RUSA 2.0 of UGC, New Delhi, India
Matrix metalloproteinases (MMPs) play roles in various pathological and physiological functions, with gelatinases as therapeutic targets against cancer. Although gelatinase inhibitors have shown effectiveness in several diseases, developing them as therapeutic agents is a challenging task. Various studies and patents have been ongoing to expand knowledge and develop better gelatinase inhibitors in recent years.
Matrix metalloproteinases (MMPs) are involved in several pathological and physiological functions. Gelatinases (MMP-2 and -9) have significant attention as therapeutic targets against cancer. Gelatinase inhibitors have demonstrated their effectiveness in several diseases including cancer. However, it is quite a challenging task to develop inhibitors as a therapeutic agent. This review summarizes the patent dedicated to the medicinal chemistry of gelatinase inhibitor reported over last decades. We examine the patent being pursued for gelatinase inhibitor development to highlight the key issues. The main aim is to provide the scientific community with an overview of the patented gelatinase inhibitors to allow further development. During early 2000s, some MMP inhibitors failed to pass the clinical trials. Hence, the lessons learned from early evidence and recent knowledge in that field will rejuvenate the development of selective inhibitors. Various studies and patents have continued in the recent years to expand knowledge. Continuously, our research team has been involved in the design of potent and selective gelatinase inhibitors for the past few years. This study is a part of our efforts. This study may be beneficial in the design and development of better gelatinase inhibitors in the future. (C) 2020 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据